Clinical Trials Details

CDK Study (ASCO)

Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK 4/6 Inhibitor Dosing Knowledge (CDK) Study

Objective

Key eligibility: HR + HER2 negative, Metastatic

> 65 years old- no prior treatment with a CDK 4/6 inhibitor

>>Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms